AstraZeneca says preliminary data from a trial shows that its COVID-19 vaccine, Vaxzevria, generated an increase in antibodies against Omicron and other variants when given as a third booster dose. AstraZeneca country president Lotis Ramin joins us.
ADVERTISEMENT
















